TMPRSS2 is a host factor that is essential for pneumotropism and pathogenicity of H7N9 influenza A virus in mice

Carolin Tarnow1, Géraldine Engels, Annika Arendt

  • 1Institute of Virology, Philipps-University Marburg, Marburg, Germany.

Journal of Virology
|February 14, 2014
PubMed
Abstract

Insights

The serine protease TMPRSS2 is crucial for H7N9 and H1N1 influenza virus pathogenicity in mice, but not for H3N2. TMPRSS2 knockout mice are resistant to H7N9 and H1N1, highlighting its role in viral infection and potential as a therapeutic target.

Area of Science:

  • Virology
  • Pathogenesis
  • Host-pathogen interactions

Background:

  • Hemagglutinin (HA) cleavage by host proteases is vital for influenza virus infectivity.
  • The serine protease TMPRSS2 activates HA in the human respiratory tract.
  • The role of TMPRSS2 in influenza virus pathogenesis in mammals is not well understood.

Purpose of the Study:

  • To investigate the role of TMPRSS2 in influenza virus pathogenesis using a mouse model.
  • To compare the replication and pathogenicity of different influenza virus subtypes (H7N9, H1N1, H3N2) in TMPRSS2 knockout and wild-type mice.

Main Methods:

  • Comparison of influenza virus replication in explants from TMPRSS2 knockout (TMPRSS2(-/-)) and wild-type (WT) mice.
  • Assessment of disease severity and mortality rates in infected TMPRSS2(-/-) and WT mice.
  • Analysis of HA cleavage by TMPRSS2 for different influenza virus subtypes.

Main Results:

  • TMPRSS2 knockout significantly inhibited H7N9 and H1N1 influenza virus replication in murine airway explants.
  • H7N9 and H1N1 viruses were apathogenic in TMPRSS2(-/-) mice, while WT mice showed severe disease and mortality.
  • H3N2 virus replication and pathogenicity were only marginally affected by TMPRSS2 knockout, indicating differential protease specificity.

Conclusions:

  • TMPRSS2 is essential for the pneumotropism and pathogenicity of H7N9 and H1N1 influenza viruses in mice.
  • Influenza viruses exhibit distinct protease specificities, with H3N2 depending on an unidentified protease.
  • HA-activating proteases, particularly TMPRSS2, represent promising therapeutic targets for influenza treatment.